tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

HRTX Stock Latest News

Heron Therapeutics Reports Strong Q3 2025 Revenue Growth
Company AnnouncementsHeron Therapeutics Reports Strong Q3 2025 Revenue Growth
9d ago
HRTX
Heron Therapeutics’ Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Heron Therapeutics’ Earnings Call: Growth Amid Challenges
9d ago
HRTX
Positive Outlook for Heron Therapeutics Driven by Zynrelef and Aponvie Growth
PremiumRatings
Positive Outlook for Heron Therapeutics Driven by Zynrelef and Aponvie Growth
9d ago
HRTX
Heron Therapeutics price target lowered to $5 from $6 at Jefferies
PremiumThe Fly
Heron Therapeutics price target lowered to $5 from $6 at Jefferies
9d ago
HRTX
Heron Therapeutics: Buy Rating Affirmed Amid Promising Product Developments and Underappreciated Market Potential
PremiumRatings
Heron Therapeutics: Buy Rating Affirmed Amid Promising Product Developments and Underappreciated Market Potential
10d ago
HRTX
Promising Growth and Strategic Initiatives Justify Buy Rating for Heron Therapeutics
PremiumRatingsPromising Growth and Strategic Initiatives Justify Buy Rating for Heron Therapeutics
10d ago
HRTX
Heron Therapeutics reports Q3 EPS (10c), consensus (1c)
Premium
The Fly
Heron Therapeutics reports Q3 EPS (10c), consensus (1c)
10d ago
HRTX
Heron Therapeutics sees FY25 revenue $153M-$163M, consensus $156.48M
Premium
The Fly
Heron Therapeutics sees FY25 revenue $153M-$163M, consensus $156.48M
10d ago
HRTX
HRTX Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
HRTX Upcoming Earnings Report: What to Expect?
12d ago
HRTX
Heron Therapeutics Appoints Thomas Cusack to Board
PremiumCompany Announcements
Heron Therapeutics Appoints Thomas Cusack to Board
15d ago
8K
HRTX
Heron Therapeutics Approves Stock Issuance Proposals
PremiumCompany Announcements
Heron Therapeutics Approves Stock Issuance Proposals
29d ago
8K
HRTX
Heron Therapeutics files $125M mixed securities shelf
PremiumThe Fly
Heron Therapeutics files $125M mixed securities shelf
2M ago
HRTX
Heron Therapeutics files to sell 37.91M shares of common stock for holders
PremiumThe FlyHeron Therapeutics files to sell 37.91M shares of common stock for holders
2M ago
HRTX
Heron Therapeutics Signs New Headquarters Lease
Premium
Company Announcements
Heron Therapeutics Signs New Headquarters Lease
3M ago
8K
HRTX
Heron Therapeutics Adopts Tax Benefit Preservation Plan
Premium
Company Announcements
Heron Therapeutics Adopts Tax Benefit Preservation Plan
3M ago
8K
HRTX
Heron Therapeutics adopts tax benefits preservation plan
PremiumThe Fly
Heron Therapeutics adopts tax benefits preservation plan
3M ago
HRTX
Heron Therapeutics’ Earnings Call Highlights Growth and Strategy
PremiumCompany Announcements
Heron Therapeutics’ Earnings Call Highlights Growth and Strategy
3M ago
HRTX
Heron Therapeutics Strengthens Financial Position with Refinancing
PremiumCompany Announcements
Heron Therapeutics Strengthens Financial Position with Refinancing
3M ago
8K
HRTX
Heron Therapeutics Signs Agreement with Patheon
PremiumCompany Announcements
Heron Therapeutics Signs Agreement with Patheon
3M ago
8K
HRTX
Heron Therapeutics Reports Strong Q2 2025 Results
PremiumCompany AnnouncementsHeron Therapeutics Reports Strong Q2 2025 Results
3M ago
HRTX
Heron Therapeutics: Buy Rating Maintained Amid Debt Restructuring and Growth Potential
Premium
Ratings
Heron Therapeutics: Buy Rating Maintained Amid Debt Restructuring and Growth Potential
3M ago
HRTX
Optimistic Outlook on Heron Therapeutics: Strategic Moves and Growth Potential Drive Buy Rating
Premium
Ratings
Optimistic Outlook on Heron Therapeutics: Strategic Moves and Growth Potential Drive Buy Rating
3M ago
HRTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >